Bryn Pharma Raises $11 Million in Financing to Advance Bi-Dose Epinephrine Nasal Spray for Anaphylaxis

Bryn Pharma, LLC ("Bryn" or the "Company"), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced that it has raised an additional $11 million in financing to fund the remaining development and regulatory approval activities, and pre-launch commercialization program for BRYN-NDS1C, its bi-dose epinephrine nasal spray. The financing was an extension of the financing transaction completed by the Company in October 2019 and brings the total proceeds from the transaction to $26 million. This was the fourth financing series completed by the Company. Participants included existing and new investors comprised of investment funds, family offices and private investors.